The IMpower133 trial evaluated the efficacy and safety of the anti-PD-L1 antibody conjugate atezolizumab in combination with carboplatin and etoposide in treatment-naive patients diagnosed with advanced SCLC.60 The gene discussed is CD274; the disease is small cell lung carcinoma.